TScan Therapeutics annual operating expenses
2020
2021
2022
2023
2024
2025
TScan Therapeutics Operating Expenses Growth & History (TCRX)
TScan Therapeutics's operating expenses was $146.1M for fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $146.1M | $8.5M | +6.18% |
| 2024 | 2024-12-31 | $137.6M | $23.1M | +20.20% |
| 2023 | 2023-12-31 | $114.5M | $34.3M | +42.83% |
| 2022 | 2022-12-31 | $80.2M | $21.4M | +36.39% |
| 2021 | 2021-12-31 | $58.8M | $31.5M | +115.18% |
| 2020 | 2020-12-31 | $27.3M | — | — |
TScan Therapeutics quarterly operating expenses
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $31.5M | −$10.2M | −24.41% |
| Q1 2026 | 2026-03-31 | $30.1M | −$8.3M | −21.60% |
| Q4 2025 | 2025-12-31 | $26.4M | −$11.0M | −29.30% |
| Q3 2025 | 2025-09-30 | $39.6M | $5.9M | +17.50% |
| Q2 2025 | 2025-06-30 | $41.7M | $7.1M | +20.43% |
| Q1 2025 | 2025-03-31 | $38.4M | $6.5M | +20.29% |
| Q4 2024 | 2024-12-31 | $37.4M | $8.8M | +30.84% |
| Q3 2024 | 2024-09-30 | $33.7M | $5.0M | +17.59% |
| Q2 2024 | 2024-06-30 | $34.6M | $6.9M | +24.83% |
| Q1 2024 | 2024-03-31 | $31.9M | $2.4M | +8.10% |
| Q4 2023 | 2023-12-31 | $28.6M | $6.8M | +31.38% |
| Q3 2023 | 2023-09-30 | $28.6M | $8.7M | +43.60% |
| Q2 2023 | 2023-06-30 | $27.8M | $8.5M | +43.81% |
| Q1 2023 | 2023-03-31 | $29.5M | $10.4M | +54.01% |
| Q4 2022 | 2022-12-31 | $21.7M | $4.7M | +27.49% |
| Q3 2022 | 2022-09-30 | $19.9M | $1.7M | +9.24% |
| Q2 2022 | 2022-06-30 | $19.3M | $5.8M | +42.69% |
| Q1 2022 | 2022-03-31 | $19.2M | $9.2M | +92.90% |
| Q4 2021 | 2021-12-31 | $17.1M | — | — |
| Q3 2021 | 2021-09-30 | $18.3M | $10.8M | +144.66% |
| Q2 2021 | 2021-06-30 | $13.5M | $7.9M | +140.87% |
| Q1 2021 | 2021-03-31 | $9.9M | — | — |
| Q3 2020 | 2020-09-30 | $7.5M | — | — |
| Q2 2020 | 2020-06-30 | $5.6M | — | — |
TScan Therapeutics operating expenses trends
Over the last five fiscal years, TScan Therapeutics's operating expenses increased from $27.3M to $146.1M, a change of $118.8M. The latest reported quarter, Q2 2026, shows $31.5M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics source filings ↗